Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Open-Label 40-week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Next Previous
Trial Profile

A Phase 3, Multicenter, Open-Label 40-week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atogepant (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors AbbVie; Allergan

Most Recent Events

  • 18 Jan 2023 Results assessing safety and tolerability of atogepant for the long-term preventive treatment of migraine published in the Headache
  • 01 Jan 2023 Results assessing the long-term safety and tolerability of atogepant for the preventive treatment of episodic migraine, published in the Cephalalgia.
  • 10 Dec 2022 Results of pooled post-hoc analysis from tow clinical studies (ADVANCE and long-term safety (LTS) trials) assessing safety and tolerability profile of atogepant presented at the 16th European headache federation COngress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top